Vitamin d derivatives

Vitamin D2 derivatives
Vitamin D4
Vitamin D3 derivatives

 

 

Calcitriol,32222-06-3
Calcitriol
Calcitriol,32222-06-3
Product Name
Calcitriol
Synonyms
1-alpha,25-Dihydroxyvitamin D3 
Systematic Name
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 
(1alpha,3beta,5Z,7E)-
CAS No.
32222-06-3
Molecular Formula 
C27H44O3
Molecular Weight
416.6416 
Price
US$480/10mg
Certificate of analysis
Calcitriol,32222-06-3
View via PDF file
Calcitriol,32222-06-3
Specification
Appearance
White crystalline powder
Complies
Identification
IR
Complies
UV
Complies
Solubility
Should comply with the request
Complies
TLC
One spot
Complies
HPLC
>99.0%
99.3%
Total impurities
<1.0%
0.5%
Unknown imp each apart from pre-Calcitriol
<0.5%
0.2%
Trans-isomer
<0.5%
0.15
1b-isomer
<0.5%
N/A
Water
3.8-5.0%
4.2%
Assay
97.0% - 103.0%
99.2%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
packing:Calcitriol,32222-06-3
Packing 1
10mg
Packing 2
100mg
Packing 3
500mg
Packing 4
1g
Packing 5
10g
Bulk request
sales@lanospharma.com
Related Vitamin D3 derivatives
Calcitriol EPVII [HOT]
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lanos' Pharmaceutical Co.,LTD ’s product(Calcitriol,32222-06-3,EPVII).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.